MedTrace Logo

A Study in Healthy People to Measure How Different Doses of Verducatib Affect the Heart

NCT07760246 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-08-12

No results posted yet for this study

Summary

The main objective of this trial is to evaluate the effects of verducatib in the range of therapeutic to supra-therapeutic exposures on the QT/QTc-interval and other ECG parameters

Conditions

  • Healthy

Interventions

DRUG

Verducatib

Verducatib

DRUG

Moxifloxacin

Moxifloxacin

DRUG

Placebo resembling Verducatib

Placebo resembling Verducatib

DRUG

Placebo resembling Moxifloxacin

Placebo resembling Moxifloxacin

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-08-17
Primary Completion
2026-12-16
Completion
2026-12-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07760246 on ClinicalTrials.gov